Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Health IT Homepage

Want to reduce readmissions? Let’s start with keeping patients healthier Insights from Robin Hill, chief clinical officer at Vivify Health

Decision support software could reduce scans by 6 percent: MIT researchers Prevent overuse of powerful and costly imaging exams

CMS to add more telehealth benefits to Medicare Advantage plans Aiming for greater flexibility, lower costs

Fredrik Palm ContextVision appoints new CEO

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

Three recommendations to better understand HIPAA compliance Approximately 70 percent of organizations are not HIPAA compliant

Researchers orchestrate malware attack to expose imaging vulnerabilities Deceived radiologists and AI algorithms into misdiagnoses

How hyper-targeting patient communications can improve medication adherence Providing specific messages can make a world of difference

Sound Imaging launches MR patient motion and detection system, SAMM MD Reduces repeat scans, prevents interruption to workflow

Where are your patients going? Keeping patients from switching to a new provider is good business and good medicine

The iTBra as seen in the
Cyrcadia Health video

Wearable device uses predictive modeling for early breast cancer detection

by John W. Mitchell , Senior Correspondent
The iTBra — a wearable device that relies on a woman's circadian rhythm to detect breast cancer lesions earlier and reduce false positives — is showing promise as researchers accumulate more data.

The developer, Cyrcadia Health, has announced it will expand the field trials for the smartphone-enabled technology to a second site at The Stefanie Spielman Comprehensive Cancer site at The Ohio State University. The company is also working on a third trail expansion internationally with the Medicine X group at Stanford University.

Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

“We typically think of medicine being performed in a clinical setting,” Rob Royea, CEO and chairman at Cyrcadia Health, told HCB News. “But our device flips that model on its head to empower the individual. We can track changes over time to find disease earlier, reduce costs and get better outcomes for women who develop breast cancer.”

He said that current testing is designed to show how the device could reduce false positives, which account for 70 percent of breast biopsies and contribute $1.6 billion in unnecessary health care spending annually.

The iTBra works by attaching a patch to each breast, similar to an EKG Holter monitor.

The device, which fits comfortably under a bra, measures and stores the body’s circadian rhythms, generated by natural light changes to a woman’s genetic make-up. According to Royea, these measurements can be collected in from two to 24 hours.

This data is then uploaded to a global cancer library site where a proprietary set of predictive algorithms analyze the information for abnormalities to indicate the presence of early breast cancer lesions.

“The analysis is fully automated with no human intervention,” said Royea. “A woman can wear the device while shopping or taking care of her children. The predictive analysis is sent to her doctor who can then follow-up with the patient.”

According to Royea, a former Johnson & Johnson and Siemens executive, there are other advantages to the iTBra. Early tests show promise in determining the difference between tissue-infused and encapsulated cancers in the milk duct of the breast. This diagnosis currently requires a biopsy — which can transfer active cancer cells to surrounding tissue — to confirm.

The device may also reduce a woman’s exposure to mammography, as well as the radiation and compression discomfort that accompany those exams, said Royea. Cyrcadia has been invited to help screen women internationally who refuse to expose their breasts to physician or hospital staff for religious reasons.

“It’s quite exciting to have The Ohio State join the current study,” said Royea. “The clinical team there had experience with an earlier version of the device that did not have the scalability of the current device.”

Health IT Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.